934-98-5

Basic information

• Product Name: 4-Methyl-1-piperazineethanamine
• Synonyms: AKOS BB-6128;4-METHYL-1-PIPERAZINEETHANAMINE;1-(2-AMINOETHYL)-4-METHYL-PIPERAZINE;2-(4-METHYLPIPERAZIN-1-YL)ETHANAMINE;2-(4-METHYL-PIPERAZIN-1-YL)-ETHYLAMINE;1-(N-AMINOETHYL)-4-METHYL PIPERAZINE;CHEMBRDG-BB 4006383;4-methylpiperazine-1-ethylamine
• CAS NO: 934-98-5
• Molecular Formula: C₇H₁₇N₃
• Molecular Weight: 143.23
• EINECS: 213-296-3
• Product Categories: Piperaizine;piperazines
• Mol File: 934-98-5.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 103°C/11.25mm
• Flash Point: 83.3 °C
• Appearance: /
• Density: 0.956 g/cm³
• Vapor Pressure: 0.148mmHg at 25°C
• Refractive Index: 1.487
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.11±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-Methyl-1-piperazineethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-1-piperazineethanamine(934-98-5)
• EPA Substance Registry System: 4-Methyl-1-piperazineethanamine(934-98-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• RIDADR: 2735
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 934-98-5(Hazardous Substances Data)

Usage

Description

4-Methyl-1-piperazineethanamine, also known as 1-(2-Aminoethyl)-4-methylpiperazine, is an organic compound with the chemical formula C6H16N2. It is a colorless liquid at room temperature and has a molecular weight of 116.21 g/mol. 4-Methyl-1-piperazineethanamine is characterized by the presence of a piperazine ring with a methyl group and an ethanamine side chain, which contributes to its unique chemical properties and potential applications.

Uses

Used in Pharmaceutical Industry:
4-Methyl-1-piperazineethanamine is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its unique chemical structure allows it to be a versatile building block in the development of new pharmaceutical compounds, particularly in the areas of central nervous system (CNS) disorders, cardiovascular diseases, and other therapeutic applications.
Used in Research and Development:
As a research chemical, 4-Methyl-1-piperazineethanamine plays a crucial role in the scientific community for the investigation of new chemical reactions, synthesis pathways, and potential applications in various fields. Researchers use this compound to explore its properties, reactivity, and interactions with other molecules, which can lead to the discovery of new drugs, materials, or processes.

InChI:InChI=1/C7H17N3/c1-9-4-6-10(3-2-8)7-5-9/h2-8H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 874-77-1 2-(4-methylpiperazin-1-yl)acetonitrile 
• 4489-39-8 2-(2-(N-methylpiperazin-4-yl)ethyl)-1H-isoindole-1,3(2H)-dione 
• 1484327-92-5 tert-butyl 2-(4-methylpiperazin-1-yl)ethylcarbamate 
• 2576-47-8 2-bromoethylamine hydrobromide 
• 107-09-5 2-bromoethylamine 
• 45813-02-3 1-methyl-4-prop-2-ynyl-piperazine 

Downstream Products

• 1484327-92-5 tert-butyl 2-(4-methylpiperazin-1-yl)ethylcarbamate 
• 600725-24-4 N-[2-(4-methyl-piperazin-1-yl)-ethyl]-benzene-1,2-diamine 
• 1616113-19-9 2-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]ethynyl]carbazol-9-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]acetamide 

Relevant articles and documents

Structural optimizations and bioevaluation of N-substituted acridone derivatives as strong topoisomerase II inhibitors

Previously, an array of N-substituted acridone derivatives have been reported as potent topoisomerase II (topo II) inhibitors, and preliminary structure–activity relationship (SAR) outcomes revealed that the linker between 1-NH and N-methyl piperazine motif of the tricyclic acridone scaffold significantly affected their anti-proliferative potencies. To further explore the SARs of acridone-derived topo II inhibitors, a wider range of novel acridone derivatives were herein synthesized via two rounds of structural optimizations on two validated hits, E17 and E24. Initially, the linker length was optimized, and then influences of N-methyl piperazinyl moiety and disposition of three N atoms on the bioactivity were investigated. As a result, a newly developed topo II inhibitor 6 h was found to be more potent than E17 and E24, thereby serving as a tool compound for the follow-up mechanistic study. Compound 6 h functioned as a strong topo IIα/β inhibitor, caused obvious DNA damage, and induced apoptosis by triggering the loss of mitochondrial membrane potential (Δψm). Further molecular docking and MD study illustrated the favorable interactions of 6 h with both topo IIα and topo IIβ subtypes.

New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity

New analogues of the recently published compound DDD107498 were prepared. Their activities were examined in vitro against the chloroquine-sensitive NF54 strain. The most active were also tested against the multiresistant K1 strain of Plasmodium falciparum. A couple of the newly synthesized compounds showed promising antiplasmodial activity and selectivity. A single compound showed adequate reduction of parasitaemia (98.1%) in mice infected with Plasmodium berghei. Survival time was doubled compared to control. The results of the biological tests of the novel compounds were compared with the activities of drugs in use. Structure-activity relationships were discussed.

BCL-3 INHIBITORS

The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure, wherein A, B, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.